Angal, lozenges [menthol], + ANTI-ANGIN® FORMULA
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Sore Throat
Conditions
Sore Throat
Trial Timeline
Feb 22, 2017 → May 7, 2017
NCT ID
NCT03095521About Angal, lozenges [menthol], + ANTI-ANGIN® FORMULA
Angal, lozenges [menthol], + ANTI-ANGIN® FORMULA is a phase 3 stage product being developed by Sandoz Group for Sore Throat. The current trial status is completed. This product is registered under clinical trial identifier NCT03095521. Target conditions include Sore Throat.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03095521 | Phase 3 | Completed |
Competing Products
5 competing products in Sore Throat
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Benzocaine 8 mg + Placebo | Johnson & Johnson | Phase 3 | 77 |
| Lidocaine 8mg + CPC 2mg + Lidocaine 1mg + CPC 2mg | Novartis | Phase 3 | 77 |
| Penciclovir + Placebo | Novartis | Approved | 85 |
| Diclofenac sodium gel 1% + Placebo | Novartis | Phase 3 | 77 |
| Angal S, topical spray [Menthol] + ANTI-ANGIN® FORMULA, topical metered spray | Sandoz Group | Phase 3 | 74 |